MARKET

PRTA

PRTA

Prothena
NASDAQ
37.80
+0.71
+1.91%
After Hours: 37.80 0 0.00% 16:20 12/07 EST
OPEN
37.28
PREV CLOSE
37.09
HIGH
39.05
LOW
36.88
VOLUME
859.14K
TURNOVER
0
52 WEEK HIGH
79.65
52 WEEK LOW
28.51
MARKET CAP
2.03B
P/E (TTM)
-26.7516
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PRTA last week (1127-1201)?
Weekly Report · 3d ago
Prothena: Statement of changes in beneficial ownership of securities
Press release · 6d ago
Prothena: Report of proposed sale of securities
Press release · 6d ago
Weekly Report: what happened at PRTA last week (1120-1124)?
Weekly Report · 11/27 09:17
Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Unprofitable companies are risky because they could burn through all their cash and become distressed. Prothena (nasdaq:prta) is an unprofitable company that has lost money for many years. But the company is not in danger of going bust and shareholders should not be worried.
Simply Wall St · 11/24 10:05
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Clinical trials for at least seven alzheimer's disease vaccines are underway or completed. Recent advances in treatments targeting toxic proteins in the brain have sparked interest in developing vaccines to combat alzheimer's. The vaccines aim to leverage the immune system to eliminate disease-related proteins from the brain. The global alzheimer's population is estimated at 39 million.
Benzinga · 11/21 20:16
Weekly Report: what happened at PRTA last week (1113-1117)?
Weekly Report · 11/20 09:18
Prothena (PRTA) Pipeline Shows Promise in a Tough AD Market
NASDAQ · 11/17 18:35
More
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.